



PATENT
Attorney Docket No.: MEDIV2010-4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Epstein et al. Art Unit: 1636
Application No.: 10/618,183 Examiner: R. Akhavan
Filing Date: July 10, 2003 Confirmation No.: 4304
Title: INJECTION OF BONE MARROW-DERIVED CELLS AND MEDIUM
FOR ANGIOGENESIS

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. § 1.97, Applicants bring the reference listed on the attached Form PTO-1449 to the attention of the Examiner for the above-identified application. A copy of the reference will be found in prior application, U.S. Serial No. 10/160,514, filed May 30, 2002, which is relied upon for an earlier filing date under 35 U.S.C. § 120.

It is respectfully requested that the reference be considered in the examination of this application and its consideration be made of written record in the application file.

09/24/2004 DENMANU1 00000004 10618183

02 FC:1806

180.00 OP

CERTIFICATION UNDER 37 CFR §1.8	
I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service with sufficient postage as first class mail on this date, September 20, 2004 , in an envelope addressed to: MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Gregory P. Austin (Name of Person Mailing Paper)	
 (Signature)	September 20, 2004 (Date)


In re Application of:
Epstein et al.
Application No.: 10/618,183
Filed: July 10, 2003
Page 2

PATENT
Attorney Docket No.: MEDIV2010-4


Enclosed is Check No. 566699 in the amount of \$235.00 in payment of the Terminal Disclaimer fee (\$55.00) and the Information Disclosure Statement submission fee (\$180.00). The Commissioner is hereby authorized to charge any other fees that may be associated with this communication, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: September 20, 2004


June M. Learn, J.D., Ph.D.
Registration No. 31,238
Telephone: (858) 677-1416
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133
USPTO CUSTOMER NO. 28213

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office 	Docket No.: MEDIV2010-4	Application No.: 10/618,183
	Applicants: Epstein et al.	Confirmation No.: 4304
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: July 10, 2003	Group Art Unit: 1636

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AA	Desgranges et al., "Beneficial use of fibroblast growth factor 2 and RGTA, a new family of heparan mimics, for endothelialization of PET prostheses", <i>J Biomed Mater Res.</i> , 2001, 58(1):1-9

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449